Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280436 · ClinicalTrials.gov registry record · Phase 2
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00280436 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 122 participants.
The verdict
NCT00280436, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
Interventions
- DRUG GW679769
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280436
The ClinicalTrials.gov registry entry for NCT00280436 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW679769 is the first listed.
NCT00280436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280436 about?
NCT00280436 is a clinical study titled "Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia". This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
What is the current status of trial NCT00280436?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2006-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00280436?
The interventions under investigation include: GW679769 (DRUG).
Who is sponsoring clinical trial NCT00280436?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.